Kolmar Korea to refinance debt borrowed for CJ Healthcare acquisition The company seeks to refinance its acquisition debt to benefit from low interest rates
Translated by Ryu Ho-joung 공개 2020-04-10 08:00:26
이 기사는 2020년 04월 10일 08:00 thebell 에 표출된 기사입니다.
Kolmar Korea, a cosmetics original development manufacturer (ODM), plans to refinance its acquisition debt in a move to take advantage of ultra-low interest rates.Kolmar Korea has appointed Samsung Securities to lead an effort to refinance 480 billion won of debt dating to its acquisition of CJ Healthcare (now HK inno.N) in 2018, sources familiar with the matter said Tuesday. Back then Kolmar Korea raised total 600 billion won to finance the acquisition and has repaid 60 billion won worth of debt each year through dividends for the last two years.
This refinancing would reduce the company’s borrowing costs significantly, with the interest rate for its debt reduced from 4.32 percent to 3.5 percent. This is partly due to a 50 basis-point rate cut announced by Bank of Korea last month.
A large reduction in borrowing costs is also attributed to CJ Healthcare’s improved earnings. Revenue of the company for 2019 rose more than 10 percent year-on-year to 542.6 billion won, while operating income increased more than 50 percent to 85.3 billion won. The revenue increase was led by growth in sales of K-CAB, a drug for gastroesophageal reflux disease (GERD), which was launched last year. For 2019, revenue from K-CAB was 34.7 billion won, the largest among all pharmaceutical products produced by the company.
Reduced debt and lower borrowing costs would help Kolmar Korea improve its financial position, which has been weakened after the acquisition of CJ Healthcare. Kolmar Korea bought CJ Healthcare for about 1.3 trillion won, of which 900 billion won came from external sources. This resulted in a sharp increase in liabilities and a downgrade of its credit rating from A0 to A-.
Kolmar Korea is also in talks with IMM Private Equity to sell non-core pharmaceutical assets. The latest balance sheet data showed that Kolmar Korea had short-term borrowings of 409.5 billion won and long-term debt of 739 billion won on a consolidated basis. The possible sale of non-core assets, combined with the refinancing, would likely reduce the company’s total debt to about 650 billion won.
“The refinancing arrangement will likely go smoothly given ultra-low interest rates and CJ Healthcare’s improved earnings,” an industry insider said.
(By reporter Jo Se-hun)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [2023 더벨 글로벌 투자 로드쇼-인도네시아]인니 정부, 친기업 정책 드라이브에 뜨거운 관심 '체감'
- [2023 더벨 글로벌 투자 로드쇼-인도네시아]"유망 스타트업 양성소, 글로벌 투자 거점 부상"
- [2023 더벨 글로벌 투자 로드쇼-인도네시아]"철저히 투자금융 관점서 봐야, 전략적 접근시 유리"
- [2023 더벨 글로벌 투자 로드쇼-베트남]신용보증기금, 중기 베트남 진출 지원에 팔 걷었다
- [2023 더벨 글로벌 투자 로드쇼-베트남]인프라·산업 투자 증가, 부동산 가격 상승 견인
- [2023 더벨 글로벌 투자 로드쇼-베트남]떠오르는 신규 투자처 '온실가스 감축 프로젝트'
- [2023 더벨 글로벌 투자 로드쇼-베트남]VITASK, 베트남 현지 기업 생산·기술력 개선 앞장
- [2023 더벨 글로벌 투자 로드쇼-베트남]급성장 '핀테크' 산업, 전자 결제·P2P·초단기 분야 각광
- [2023 더벨 글로벌 투자 로드쇼-베트남]진출 계획시 세무 접근 필요, '우대세율·감면' 활용해야 '득'
- [2023 더벨 글로벌 투자 로드쇼-베트남]한국이 투자 주춤할 때 태국은 과감히 '베팅'